Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
METLUNG: Metformin + TKIs in Advanced NSCLC with EGFR Mutations
NCT05445791Phase 3Recruiting
- Start
- Jul 2021
- Primary completion
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in non-small cell lung cancer (NSCLC) comparing Placebo with Metformin (2 arms). Primary endpoint: Progression-Free Survival at 48 months. Started Jul 2021; status: recruiting.
02
Drugs
metformin
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05445791.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05445791.